articleThe LancetAug 27, 2012Closed access

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

Brigham and Women's Hospital · Medical University of South Carolina · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,164
total citations
FWCI
45.72
Percentile
100%
References
43
Citations per year

Authors

13

Topics & keywords

Keywords
  • Neprilysin
  • Ejection fraction
  • Heart failure
  • Medicine
  • Double blind
  • Cardiology
  • Angiotensin receptor
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.